Pfizer’s Biosimilar Program: A MAB Dash After Biocon Deal Ends
This article was originally published in PharmAsia News
Executive Summary
Following the breakup in March of its insulin biosimilars deal with Biocon, Pfizer confirms plans to develop monoclonal antibody biosimilars on its own, and has put its first candidate, rituximab, into Phase 1 testing.